Gland Pharma Limited (NSE: GLAND) reported Revenue from Operations of ₹938.28 Crore down from ₹1,063.32 Crore year on year, a decline of 11.8%. Consolidated Net Profit of ₹231.94 Crore, slumped 15% from ₹273 Crore in the same quarter of the previous year. The Earnings per Share is ₹14.08 for this quarter.
Gland Pharma Limited Q3 FY23; Net Profit Down To 232 Crore
Related Post
- Syngene Q3 FY26 Earnings Results
Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO)…
-
Grindwell Norton Q2 FY26 Earnings Results
Grindwell Norton Limited, engaged in manufacturing abrasives, ceramics & plastics and providing IT services, reported…
-
H.G. Infra Q2 FY26 Earnings Results
H.G. Infra Engineering Limited (HGIEL), an Indian road infrastructure company engaged in EPC services, maintenance…